Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer.
Breast cancer
Gastric varices
Portal hypertension
Portal-systemic shunt
Sinusoidal obstruction syndrome
Trastuzumab emtansine
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
25
09
2019
accepted:
08
10
2019
entrez:
18
1
2020
pubmed:
18
1
2020
medline:
18
1
2020
Statut:
epublish
Résumé
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for use in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Here, we present the cases of two patients with metastatic breast cancer who received T-DM1 monotherapy and developed noncirrhotic portal hypertension (NCPH). Patient 1 presented with ruptured gastric varices at 2 years and 5 months after T-DM1 treatment. Patient 2 presented with intrahepatic portal-hepatic venous shunt at 2 years and 6 months and portal-systemic shunt encephalopathy at 4 years and 11 months after T-DM1 treatment. In both the patients, liver biopsies revealed sinusoidal obstruction syndrome (SOS). T-DM1-induced hepatotoxicity can result from SOS. In long-term administration of T-DM1 the unfavorable events associated with chronic liver circulatory disorder due to SOS, such as NCPH, are concerning.
Identifiants
pubmed: 31950012
doi: 10.1007/s13691-019-00392-4
pii: 392
pmc: PMC6942611
doi:
Types de publication
Case Reports
Langues
eng
Pagination
18-23Informations de copyright
© The Japan Society of Clinical Oncology 2019.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Chem Pharm Bull (Tokyo). 2004 Jan;52(1):1-26
pubmed: 14709862
HPB (Oxford). 2013 Nov;15(11):858-64
pubmed: 23458554
Mod Pathol. 2006 Oct;19(10):1302-9
pubmed: 16763611
Ann Oncol. 2004 Mar;15(3):460-6
pubmed: 14998849
Hepatology. 2009 Mar;49(3):1017-44
pubmed: 19243014
J Clin Oncol. 2016 Jan 20;34(3):e9-12
pubmed: 24778392
Intern Med. 2017;56(4):395-400
pubmed: 28202860
Cancer Immunol Immunother. 2013 Feb;62(2):217-23
pubmed: 23223907
J Clin Oncol. 2010 May 20;28(15):2549-55
pubmed: 20406923
Ann Surg Oncol. 2013 May;20(5):1462-9
pubmed: 23463086
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Ann Pharmacother. 2008 Oct;42(10):1497-501
pubmed: 18780811
Hepatology. 2000 Feb;31(2):428-34
pubmed: 10655267
Gastroenterology. 2003 Sep;125(3):882-90
pubmed: 12949732
Mol Cancer Ther. 2016 Mar;15(3):480-90
pubmed: 26712117
Science. 1975 Sep 19;189(4207):1002-5
pubmed: 1241159
Toxicol Appl Pharmacol. 2013 Dec 1;273(2):298-313
pubmed: 24035823